



Certificate No: IT-API/99/H/2017

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER

Part 1

Issued following an inspection in accordance with Art. 111(5) of Directive 2001/83/EC

The competent authority of Italy confirms the following:

The manufacturer SICOR SOCIETA' ITALIANA CORTICOSTEROIDI S.R.L.

Site address Via Terrazzano, 77 - 20017 RHO (MI)

Is an active substance manufacturer that has been inspected in accordance with Art. 111(1) of Directive 2001/83/EC transposed in the following national legislation: D.L. n. 219 of 24th April 2006 art. 53

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 2016/04/15, it is considered that it complies with the Good Manufacturing Practice requirements referred to in the principles of GMP for active substances referred to in Article 47 of Directive 2001/83/EC.

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. The authenticity of this certificate may be verified in EudraGMP. If it does not appear, please contact the issuing authority.



AIFA - Italian Medicines Agency
GMP Inspections and Manufacturing Authorizations of APIs Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel +39065978401 Fax +390659784617
website: www.agenziafarmaco.it
SIS : 1007

VI
GMP



Agenzia Italiana del Farmaco

AIFA

Part 2

Name and address of the site:

**SICOR SOCIETA' ITALIANA CORTICOSTEROIDI S.R.L. - Via Terrazzano,
77, 20017 RHO (MI)**

Name of the active Substances manufactured or imported:

PAMIDRONIC ACID
AMCINONIDE
ANSAMITOCIN
ATRACURIUM BESILATE
BECLOMETASONE DIPROPIONATE
BECLOMETASONE DIPROPIONATE ANHYDROUS
BETAMETHASONE
BETAMETHASONE ACETATE
BETAMETHASONE DIPROPIONATE
BETAMETHASONE SODIUM PHOSPHATE
BETAMETHASONE VALERATE
BLEOMYCIN SULFATE
CICLOSPORIN
CISATRACURIUM BESILATE
CLOBETASOL PROPIONATE
DAUNORUBICIN HYDROCHLORIDE
DESONIDE
DESOXYCORTICOSTERONE PIVALATE
DESOXYCORTONE ACETATE
DEXRAZOXANE
DIFLORASONE DIACETATE
DIFLUPREDNATE
FLUDARABINE PHOSPHATE
FLUDROCORTISONE ACETATE
FLUNISOLIDE
FLUOCINOLONE ACETONIDE
FLUOCINONIDE
FLUOROMETHOLONE
FLUOROMETHOLONE ACETATE

AIFA - Italian Medicines Agency
GMP Inspections and Manufacturing Authorizations of APIs Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel +39065978401 Fax +390659784617
website: www.agenziafarmaco.it
SIS - 1007

VI
GMP



Agenzia Italiana del Farmaco

AIFA

FORMOTEROL FUMARATE DIHYDRATE
FULVESTRANT
HYDROCORTISONE
MITOMYCIN
PANCURONIUM BROMIDE
PRASTERONE CRUDE
PREDNISOLONE
ROMIDEPSIN
SCOPOLAMINE HYDROBROMIDE TRIHYDRATE CRUDE
TRIAMCINOLONE
TRIAMCINOLONE ACETONIDE
VECURONIUM BROMIDE

3 - Manufacturing Operations - Active Substances

PAMIDRONIC ACID

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity
	3.1.2. Manufacture of crude active substance
	3.1.3. Salt formation / Purification steps: crystallisation
3.5	General Finishing Steps
	3.5.1. Physical processing steps drying
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

AIFA - Italian Medicines Agency
GMP Inspections and Manufacturing Authorizations of APIs Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel +39065978401 Fax +390659784617
website: www.agenziafarmaco.it
SIS : 1007

VI
GMP



Agenzia Italiana del Farmaco

AIFA

3 - Manufacturing Operations - Active Substances **AMCINONIDE**

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity
	3.1.2. Manufacture of crude active substance
	3.1.3. Salt formation / Purification steps: crystallisation
3.5	General Finishing Steps
	3.5.1. Physical processing steps drying
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances **ANSAMITOCIN**

3.3	Manufacture of Active Substance using Biological Processes
	3.3.1. Fermentation Special Requirements Other: Cytotoxic
	3.3.3. Isolation / Purification
3.5	General Finishing Steps
	3.5.1. Physical processing steps drying
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
	3.5.3. Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the

AIFA - Italian Medicines Agency
GMP Inspections and Manufacturing Authorizations of APIs Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel +39065978401 Fax +390659784617
website: www.agenziafarmaco.it
SIS : 1007

VI
GMP



Agenzia Italiana del Farmaco

AIFA



	material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances ATRACURIUM BESILATE

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1. Manufacture of active substance intermediates 3.1.2. Manufacture of crude active substance 3.1.3. Salt formation / Purification steps: chromatography, precipitation
3.5	General Finishing Steps
	3.5.1. Physical processing steps drying 3.5.2. Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances BECLOMETASONE DIPROPIONATE

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity 3.1.2. Manufacture of crude active substance 3.1.3. Salt formation / Purification steps: crystallisation
3.5	General Finishing Steps
	3.5.1. Physical processing steps

AIFA - Italian Medicines Agency
GMP Inspections and Manufacturing Authorizations of APIs Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel +39065978401 Fax +390659784617
website: www.agenziafarmaco.it
SIS : 1007

VI
GMP



Agenzia Italiana del Farmaco

AIFA

	drying
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances BECLOMETASONE DIPROPIONATE ANHYDROUS

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity
	3.1.2. Manufacture of crude active substance
	3.1.3. Salt formation / Purification steps: crystallisation
3.5	General Finishing Steps
	3.5.1. Physical processing steps drying
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances BETAMETHASONE

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity
	3.1.2. Manufacture of crude active substance
	3.1.3. Salt formation / Purification steps:

AIFA - Italian Medicines Agency
GMP Inspections and Manufacturing Authorizations of APIs Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel +39065978401 Fax +390659784617
website: www.agenziafarmaco.it
SIS : 1007

VI
GMP



Agenzia Italiana del Farmaco

AIFA

	precipitation
3.5	General Finishing Steps
	3.5.1. Physical processing steps drying
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances **BETAMETHASONE ACETATE**

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity
	3.1.2. Manufacture of crude active substance
	3.1.3. Salt formation / Purification steps: crystallisation
3.5	General Finishing Steps
	3.5.1. Physical processing steps drying, milling
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances **BETAMETHASONE DIPROPIONATE**

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1. Manufacture of active substance intermediates Special Requirements

AIFA - Italian Medicines Agency
GMP Inspections and Manufacturing Authorizations of APIs Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel +39065978401 Fax +390659784617
website: www.agenziafarmaco.it
SIS : 1007

VI
GMP



Agenzia Italiana del Farmaco

AIFA

	Other: Hormones or substances with hormonal activity
	3.1.2. Manufacture of crude active substance
	3.1.3. Salt formation / Purification steps: precipitation
3.5	General Finishing Steps
	3.5.1. Physical processing steps drying
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances BETAMETHASONE SODIUM PHOSPHATE

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity
	3.1.2. Manufacture of crude active substance
	3.1.3. Salt formation / Purification steps: precipitation
3.5	General Finishing Steps
	3.5.1. Physical processing steps drying
3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances BETAMETHASONE VALERATE

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1. Manufacture of active substance intermediates

AIFA - Italian Medicines Agency
GMP Inspections and Manufacturing Authorizations of APIs Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel. +39065978401 Fax +390659784617
website: www.agenziafarmaco.it
SIS : 1007

VI
GMP



Agenzia Italiana del Farmaco

AIFA



	Special Requirements
	Other: Hormones or substances with hormonal activity
	3.1.2. Manufacture of crude active substance
	3.1.3. Salt formation / Purification steps: precipitation
3.5	General Finishing Steps
	3.5.1. Physical processing steps drying
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances BLEOMYCIN SULFATE

3.3	Manufacture of Active Substance using Biological Processes
	3.3.1. Fermentation Special Requirements Other: Cytotoxic
	3.3.3. Isolation / Purification
3.5	General Finishing Steps
	3.5.1. Physical processing steps drying
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances CICLOSPORIN

3.3	Manufacture of Active Substance using Biological Processes
------------	---

AIFA - Italian Medicines Agency
GMP Inspections and Manufacturing Authorizations of APIs Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel. +39065978401 Fax +390659784617
website: www.agenziafarmaco.it
SIS: 1007

VI
GMP



Agenzia Italiana del Farmaco

AIFA

	3.3.3. Isolation / Purification
3.5	General Finishing Steps
	3.5.1. Physical processing steps drying
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
	3.5.3. Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances

CISATRACURIUM BESILATE

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1. Manufacture of active substance intermediates
	3.1.2. Manufacture of crude active substance
	3.1.3. Salt formation / Purification steps: chromatography, precipitation
3.5	General Finishing Steps
	3.5.1. Physical processing steps drying
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances

CLOBETASOL PROPIONATE

3.1	Manufacture of Active Substance by Chemical Synthesis
------------	--

AIFA - Italian Medicines Agency
GMP Inspections and Manufacturing Authorizations of APIs Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel. +39065978401 Fax +390659784617
website: www.agenziafarmaco.it
SIS : 1007

VI
GMP



Agenzia Italiana del Farmaco

AIFA

	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity
	3.1.2. Manufacture of crude active substance
	3.1.3. Salt formation / Purification steps: precipitation
3.5	General Finishing Steps
	3.5.1. Physical processing steps drying
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances
DAUNORUBICIN HYDROCHLORIDE

3.3	Manufacture of Active Substance using Biological Processes
	3.3.1. Fermentation Special Requirements Other: Cytotoxic
	3.3.3. Isolation / Purification
3.5	General Finishing Steps
	3.5.1. Physical processing steps drying
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

AIFA - Italian Medicines Agency
GMP Inspections and Manufacturing Authorizations of APIs Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel. +39065978401 Fax +390659784617
website: www.agenziafarmaco.it
SIS : 1007

VI
GMP



Agenzia Italiana del Farmaco

AIFA

3 - Manufacturing Operations - Active Substances

DESONIDE

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity
	3.1.2. Manufacture of crude active substance
	3.1.3. Salt formation / Purification steps: precipitation
3.5	General Finishing Steps
	3.5.1. Physical processing steps drying
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances

DESOXYCORTICOSTERONE PIVALATE

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity
	3.1.2. Manufacture of crude active substance
	3.1.3. Salt formation / Purification steps: precipitation
3.5	General Finishing Steps
	3.5.1. Physical processing steps drying
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)

AIFA - Italian Medicines Agency
GMP Inspections and Manufacturing Authorizations of APIs Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel. +39065978401 Fax +390659784617
website: www.agenziafarmaco.it
SIS : 1007

VI
GMP



Agenzia Italiana del Farmaco
AIFA



3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances DEXRAZOXANE

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1. Manufacture of active substance intermediates 3.1.2. Manufacture of crude active substance 3.1.3. Salt formation / Purification steps: precipitation
3.5	General Finishing Steps
	3.5.1. Physical processing steps drying 3.5.2. Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3. Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances DIFLORASONE DIACETATE

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity 3.1.2. Manufacture of crude active substance 3.1.3. Salt formation / Purification steps: precipitation

AIFA - Italian Medicines Agency
GMP Inspections and Manufacturing Authorizations of APIs Office
Via dei Tritone, n° 181 - 00187 ROMA (ITALY)
Tel +39065978401 Fax +390659784617
website: www.agenziafarmaco.it
SIS : 1007

VI
GMP



Agenzia Italiana del Farmaco

AIFA

3.5	General Finishing Steps
	3.5.1. Physical processing steps drying
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances DIFLUPREDNATE

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity
	3.1.2. Manufacture of crude active substance
	3.1.3. Salt formation / Purification steps: precipitation
3.5	General Finishing Steps
	3.5.1. Physical processing steps drying
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances FLUDARABINE PHOSPHATE

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Cytotoxic

AIFA - Italian Medicines Agency
GMP Inspections and Manufacturing Authorizations of APIs Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel. +39065978401 Fax +390659784617
website: www.agenziafarmaco.it
SIS : 1007

VI
GMP



Agenzia Italiana del Farmaco

AIFA

	3.1.2. Manufacture of crude active substance
	3.1.3. Salt formation / Purification steps: precipitation
3.5	General Finishing Steps
	3.5.1. Physical processing steps drying
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances FLUDROCORTISONE ACETATE

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity
	3.1.2. Manufacture of crude active substance
	3.1.3. Salt formation / Purification steps: precipitation
3.5	General Finishing Steps
	3.5.1. Physical processing steps drying
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances FLUNISOLIDE

3.1 Manufacture of Active Substance by Chemical Synthesis

AIFA - Italian Medicines Agency
GMP Inspections and Manufacturing Authorizations of APIs Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel +39065978401 Fax +390659784617
website: www.agenziafarmaco.it
SIS : 1007

VI
GMP



Agenzia Italiana del Farmaco

AIFA

	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity
	3.1.2. Manufacture of crude active substance
	3.1.3. Salt formation / Purification steps: precipitation
3.5	General Finishing Steps
	3.5.1. Physical processing steps drying
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances
FLUOCINOLONE ACETONIDE

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity
	3.1.2. Manufacture of crude active substance
	3.1.3. Salt formation / Purification steps: precipitation
3.5	General Finishing Steps
	3.5.1. Physical processing steps drying
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

AIFA - Italian Medicines Agency
GMP Inspections and Manufacturing Authorizations of APIs Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel +39065978401 Fax +390659784617
website: www.agenziafarmaco.it
SIS : 1007

VI
GMP



Agenzia Italiana del Farmaco

AIFA



3 - Manufacturing Operations - Active Substances FLUOCINONIDE

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity
	3.1.2. Manufacture of crude active substance
	3.1.3. Salt formation / Purification steps: precipitation
3.5	General Finishing Steps
	3.5.1. Physical processing steps drying
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances FLUOROMETHOLONE

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity
	3.1.2. Manufacture of crude active substance
	3.1.3. Salt formation / Purification steps: crystallisation
3.5	General Finishing Steps
	3.5.1. Physical processing steps drying
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)

AIFA - Italian Medicines Agency
GMP Inspections and Manufacturing Authorizations of APIs Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel. +39065978401 Fax +390659784617
website: www.agenziafarmaco.it
SIS : 1007

VI
GMP



Agenzia Italiana del Farmaco

AIFA

3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances **FLUOROMETHOLONE ACETATE**

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity
	3.1.2. Manufacture of crude active substance
	3.1.3. Salt formation / Purification steps: precipitation
3.5	General Finishing Steps
	3.5.1. Physical processing steps drying
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances **FORMOTEROL FUMARATE DIHYDRATE**

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1. Manufacture of active substance intermediates
	3.1.2. Manufacture of crude active substance
	3.1.3. Salt formation / Purification steps: precipitation
3.5	General Finishing Steps
	3.5.1. Physical processing steps drying
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a

AIFA - Italian Medicines Agency
GMP Inspections and Manufacturing Authorizations of APIs Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel. +39065978401 Fax +390659784617
website: www.agenziafarmaco.it
SIS : 1007

VI
GMP



Agenzia Italiana del Farmaco

AIFA

	packaging material which is in direct contact with the substance)
3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances **FULVESTRANT**

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity
	3.1.2. Manufacture of crude active substance
	3.1.3. Salt formation / Purification steps: crystallisation
	General Finishing Steps
	3.5.1. Physical processing steps drying
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances **MITOMYCIN**

3.3	Manufacture of Active Substance using Biological Processes
	3.3.1. Fermentation Special Requirements Other: Cytotoxic
	3.3.3. Isolation / Purification
3.5	General Finishing Steps
	3.5.1. Physical processing steps drying, sieving

AIFA - Italian Medicines Agency
GMP Inspections and Manufacturing Authorizations of APIs Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel. +39065978401 Fax +390659784617
website: www.agenziafarmaco.it
SIS : 1007

VI
GMP



Agenzia Italiana del Farmaco

AIFA

	3.5.2. Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances PANCURONIUM BROMIDE

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1. Manufacture of active substance intermediates
	3.1.2. Manufacture of crude active substance
	3.1.3. Salt formation / Purification steps: precipitation
3.5	General Finishing Steps
	3.5.1. Physical processing steps drying
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances ROMIDEPSIN

3.3	Manufacture of Active Substance using Biological Processes
	3.3.1. Fermentation Special Requirements Other: Cytotoxic
	3.3.3. Isolation / Purification
3.5	General Finishing Steps
	3.5.1. Physical processing steps drying
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a

AIFA - Italian Medicines Agency
GMP Inspections and Manufacturing Authorizations of APIs Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel +39065978401 Fax +390659784617
website: www.agenziafarmaco.it
SIS : 1007

VI
GMP



Agenzia Italiana del Farmaco

AIFA

	packaging material which is in direct contact with the substance)
3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances TRIAMCINOLONE

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity
	3.1.2. Manufacture of crude active substance
	3.1.3. Salt formation / Purification steps: precipitation
3.5	General Finishing Steps
	3.5.1. Physical processing steps drying
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances TRIAMCINOLONE ACETONIDE

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1. Manufacture of active substance intermediates Special Requirements Other: Hormones or substances with hormonal activity
	3.1.2. Manufacture of crude active substance
	3.1.3. Salt formation / Purification steps: precipitation
3.5	General Finishing Steps

AIFA - Italian Medicines Agency
GMP Inspections and Manufacturing Authorizations of APIs Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel. +39065978401 Fax +390659784617
website: www.agenziafarmaco.it
SIS : 1007

VI
GMP



Agenzia Italiana del Farmaco

AIFA

	3.5.1. Physical processing steps drying
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

3 - Manufacturing Operations - Active Substances VECURONIUM BROMIDE

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1. Manufacture of active substance intermediates
	3.1.2. Manufacture of crude active substance
	3.1.3. Salt formation / Purification steps: precipitation
3.5	General Finishing Steps
	3.5.1. Physical processing steps drying
	3.5.2. Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.6	Quality Control Testing
	3.6.1. Physical / Chemical testing

4. Other Activities - Active Substance:

Importation of:

DESOXYCORTONE ACETATE (Confidential); HYDROCORTISONE (Confidential); PRASTERONE
CRUDE (Confidential); PREDNISOLONE (Confidential); SCOPOLAMINE HYDROBROMIDE
TRIHYDRATE CRUDE (Confidential)

AIFA - Italian Medicines Agency
GMP Inspections and Manufacturing Authorizations of APIs Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel. +39065978401 Fax +390659784617
website: www.agenziafarmaco.it
SIS : 1007

VI
GMP



Agenzia Italiana del Farmaco

AIFA

Restrictions or clarifying remarks:

Imported active substances marked as confidential undergo further processing within the importing site. The Inspectorate adopted a risk-based approach for planning of inspections, therefore the validity of the GMP certificate for this manufacturing site is not more than 24 months from the last general GMP inspection, which was conducted on 2016/04/15. It will still be AIFA's right to re-evaluate the validity of the GMP certificate based on risk profile changes.

Rome, 2017/07/19

**Name and signature of the authorised person of
the Competent Authority of Republic of Italy**



Marisa Delbò

Dott.ssa Marisa Delbò

**AIFA - GMP Inspections and Manufacturing
Authorizations of APIs Office**



AIFA - Italian Medicines Agency
GMP Inspections and Manufacturing Authorizations of APIs Office
Via del Tritone, n° 181 - 00187 ROMA (ITALY)
Tel +39065978401 Fax +390659784617
website: www.agenziafarmaco.it
SIS : 1007

VI
GMP

004768

Attesto io sottoscritto Dr. Federico
Prinetti

Notaio in Milano che la presente copia fotografica
in 23 fogli

è conforme all'originale documento statomi esibito

Milano **27 MARZO 2018**



APOSTILLE

(Convenzione de la Haye du 5 octobre 1961)

1. Paese ITALIA
- Il presente atto pubblico
2. è stato sottoscritto da F. Prinetti
3. agente in qualità di Notaio
4. e segnato dal contrassegno/timbro di Prinetti
- Attestato
5. a Milano, il -4 APR. 2018
7. dell'ufficio del pubblico ministero
8. sotto il numero 4962
9. contrassegno unico Prinetti

Il Sost. Procuratore della Repubblica
Dr.ssa Rossana GUARESCHI



OFFICE OF THE CONTROLLER FOOD AND DRUGS ADMINISTRATION
MADHYA PRADESH



Form 26

[See Rules 73 and 83]

Certificate of renewal of licence to manufacture for sale
of drugs other than those specified in Schedule X

1. Certified that licence No: 25/35/83 granted on the 03-Jan-1989 to MR.A.K.JAIN S/W/D/O MR. BHANWARLAL JAIN DIRECTOR AND OTHER(S) OF IPCA LABORATORIES LTD. for the manufacture of the following categories of drugs being drugs other than those specified in Schedules C, C(1) and X/drugs specified in Schedules C and C(1) excluding those specified in Schedule X to the Drugs and Cosmetics Rules, 1945, at the premises situated at P.O. Sejavta, Dist. Ratlam Madhya Pradesh has been renewed from 01-Jan-2017 to 31-Dec-2021
2. Name(s) of approved [Competent technical staff] (List enclosed of 53 Competent/Expert/Technical Staff).
3. Names of the drugs (each item to be separately specified) (List enclosed of 1515 Item(s)).

Signature valid

Digitally Signed By RAJNEESH CHOWDHARY
(Food and Drugs Administration)
Date : 08-Mar-2017 18:45:38 IST

Date : 04-Mar-2017

LICENSING AUTHORITY
FOOD AND DRUGS ADMINISTRATION
MADHYA PRADESH



CERTIFIED TRUE COPY

M

JAGDISH TRYAMBAK DONGARDIVE
Advocate & Notary, (Govt. Of India)
Saraswati Chawl, Kranti Nagar,
Zupadpatti, Akurli Road,
Kandivalli (E), Mumbai-400 10*
(Maharashtra)



ATTESTED BY

Pramod S. Uchil

Assistant Director



OFFICE OF THE CONTROLLER FOOD AND DRUGS ADMINISTRATION
MADHYA PRADESH

Ipca Laboratories Ltd., District-RATLAM

MFG. LIC NO. : 25/35/83
Valid Upto : 31-Dec-2021

List of Product(s)

S.No.	Product Name	Composition
1.	2-4 DICHLORO BENZYL ALCOHOL Active Pharmaceutical Ingredients (Bulk Drugs)	
2.	ARTEMETHER Active Pharmaceutical Ingredients (Bulk Drugs)	
3.	ARTEMETHER IP Active Pharmaceutical Ingredients (Bulk Drugs)	
4.	α - β ARTEETHER Active Pharmaceutical Ingredients (Bulk Drugs)	
5.	ARTEETHER (α - β ARTEETHER) IP Active Pharmaceutical Ingredients (Bulk Drugs)	
6.	ACECLOFENAC IP/BP/Ph.Eur. Active Pharmaceutical Ingredients (Bulk Drugs)	
7.	ALENDRONATE SODIUM USP Active Pharmaceutical Ingredients (Bulk Drugs)	
8.	ALENDRONIC ACID USP Active Pharmaceutical Ingredients (Bulk Drugs)	
9.	ALLOPURINOL IP Active Pharmaceutical Ingredients (Bulk Drugs)	
10.	AMODIAQUINE USP Active Pharmaceutical Ingredients (Bulk Drugs)	
11.	AMODIAQUINE HYDROCHLORIDE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
12.	AMLODIPINE BESYLATE IP/BP/USP/EP Active Pharmaceutical Ingredients (Bulk Drugs)	
13.	AMYLMETACRESOL BP/Ph.Eur Active Pharmaceutical Ingredients (Bulk Drugs)	
14.	ARTEETHER Active Pharmaceutical Ingredients (Bulk Drugs)	
15.	ARTEETHER IP Active Pharmaceutical Ingredients (Bulk Drugs)	
16.	ARTEMOTIL Int.Ph. Active Pharmaceutical Ingredients (Bulk Drugs)	
17.	ARTESUNATE Active Pharmaceutical Ingredients (Bulk Drugs)	
18.	ARTESUNATE IP/Int.Ph. Active Pharmaceutical Ingredients (Bulk Drugs)	
19.	ARTESUNATE (STERILE) Active Pharmaceutical Ingredients (Bulk Drugs)	



21.	ATENOLOL IP Active Pharmaceutical Ingredients (Bulk Drugs)	
22.	ALFUZOSIN HYDROCHLORIDE BP/USP Active Pharmaceutical Ingredients (Bulk Drugs)	
23.	ALFUZOSIN HYDROCHLORIDE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
24.	AMLODIPINE BESILATE JP Active Pharmaceutical Ingredients (Bulk Drugs)	
25.	BENDROFLUMETHIAZIDE BP/Ph.Eur/CP/JP/USP Active Pharmaceutical Ingredients (Bulk Drugs)	
26.	BALSALAZIDE DISODIUM DIHYDRATE Active Pharmaceutical Ingredients (Bulk Drugs)	
27.	BISOPROLOL FUMARATE USP/EP Active Pharmaceutical Ingredients (Bulk Drugs)	
28.	BISOPROLOL FUMARATE CP Active Pharmaceutical Ingredients (Bulk Drugs)	
29.	BROMHEXINE HYDROCHLORIDE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
30.	BULAQUINE Active Pharmaceutical Ingredients (Bulk Drugs)	
31.	BUPROPION HYDROCHLORIDE USP Active Pharmaceutical Ingredients (Bulk Drugs)	
32.	CANDESARTAN CILEXETIL Active Pharmaceutical Ingredients (Bulk Drugs)	
33.	CARVEDILOL IP/BP/Ph.Eur./USP Active Pharmaceutical Ingredients (Bulk Drugs)	
34.	CELECOXIB Active Pharmaceutical Ingredients (Bulk Drugs)	
35.	CETIRIZINE HYDROCHLORIDE /CETIRIZINE DIHYDROCHLORIDE IP/BP/Ph.Eur. Active Pharmaceutical Ingredients (Bulk Drugs)	
36.	CHLOROQUINE PHOSPHATE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
37.	CHLOROQUINE SULPHATE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
38.	CHLORTHALIDONE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
39.	CILOSTAZOL Active Pharmaceutical Ingredients (Bulk Drugs)	
40.	CILOSTAZOL IP Active Pharmaceutical Ingredients (Bulk Drugs)	
41.	CILOSTAZOL USP/JPC Active Pharmaceutical Ingredients (Bulk Drugs)	
42.	CITALOPRAM HYDROBROMIDE Active Pharmaceutical Ingredients (Bulk Drugs)	

42.	ESCITALOPRAM HYDROBROMIDE IP/USP/BP/EP Active Pharmaceutical Ingredients (Bulk Drugs)	
43.	CLOPIDOGREL BISULFATE / CLOPIDOGREL BISULPHATE IP/USP Active Pharmaceutical Ingredients (Bulk Drugs)	
44.	CLOPIDOGREL BISULPHATE Active Pharmaceutical Ingredients (Bulk Drugs)	
45.	CLOZAPINE IP/USP/Ph.Eur/CP Active Pharmaceutical Ingredients (Bulk Drugs)	
46.	DIHYDROARTEMISININE Active Pharmaceutical Ingredients (Bulk Drugs)	
47.	DIHYDROARTEMISININ Int.Ph. Active Pharmaceutical Ingredients (Bulk Drugs)	
48.	DIPHENHYDRAMINE HYDROCHLORIDE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
49.	DULOXETINE HYDROCHLORIDE Active Pharmaceutical Ingredients (Bulk Drugs)	
50.	ESCITALOPRAM OXALATE USP Active Pharmaceutical Ingredients (Bulk Drugs)	
51.	ESOMEPRAZOLE MAGNESIUM IP Active Pharmaceutical Ingredients (Bulk Drugs)	
52.	ESZOPICHLONE USP Active Pharmaceutical Ingredients (Bulk Drugs)	
53.	ETODOLAC IP/BP/Ph.Eur./USP/IP Active Pharmaceutical Ingredients (Bulk Drugs)	
54.	ETODOLAC SODIUM Active Pharmaceutical Ingredients (Bulk Drugs)	
55.	EZETIMIBE Active Pharmaceutical Ingredients (Bulk Drugs)	
56.	ESOMEPRAZOLE MAGNESIUM USP Active Pharmaceutical Ingredients (Bulk Drugs)	
57.	EBASTINE BP/Ph.Eur. Active Pharmaceutical Ingredients (Bulk Drugs)	
58.	EBASTINE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
59.	FENOFIBRATE IP/BP/Ph.Eur./USP Active Pharmaceutical Ingredients (Bulk Drugs)	
60.	FLUCONAZOLE Active Pharmaceutical Ingredients (Bulk Drugs)	
61.	FLUCONAZOLE IP/BP/Ph.Eur./USP/CP Active Pharmaceutical Ingredients (Bulk Drugs)	
62.	FLUMEQUINE EP VET Active Pharmaceutical Ingredients (Bulk Drugs)	
63.	FRUSEMIDE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
64.	FURALTADONE HYDROCHLORIDE Active Pharmaceutical Ingredients (Bulk Drugs)	



65.	FAMOTIDINE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
66.	GABAPENTIN USP Active Pharmaceutical Ingredients (Bulk Drugs)	
67.	GLIMEPIRIDE Active Pharmaceutical Ingredients (Bulk Drugs)	
68.	GLIMEPIRIDE IP/BP/Ph.Eur./USP Active Pharmaceutical Ingredients (Bulk Drugs)	
69.	GLIPIZIDE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
70.	GLIPIZIDE USP/Ph.Eur./CP Active Pharmaceutical Ingredients (Bulk Drugs)	
71.	GLICLAZIDE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
72.	GLICLAZIDE Ph.Eur./BP/IP Active Pharmaceutical Ingredients (Bulk Drugs)	
73.	HYDROCHLOROTHIAZIDE IP/IP Active Pharmaceutical Ingredients (Bulk Drugs)	
74.	HYDROXYCHLOROQUINE SULPHATE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
75.	HYDROXYZINE HYDROCHLORIDE IP. Active Pharmaceutical Ingredients (Bulk Drugs)	
76.	HYDROXYCHLOROQUINE SULFATE USP/BP/Ph.Eur. Active Pharmaceutical Ingredients (Bulk Drugs)	
77.	HYDROXYZINE DIHYDROCHLORIDE BP/USP/EP Active Pharmaceutical Ingredients (Bulk Drugs)	
78.	HYDRALAZINE HYDROCHLORIDE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
79.	INDAPAMIDE BP/Ph.Eur./CP/USP Active Pharmaceutical Ingredients (Bulk Drugs)	
80.	IRBESARTAN Ph.Eur./USP Active Pharmaceutical Ingredients (Bulk Drugs)	
81.	INDAPAMIDE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
82.	IRBESARTAN IP Active Pharmaceutical Ingredients (Bulk Drugs)	
83.	ISOPROPYL ALCOHOL (2- PROPANOL;PROPAN-2-OL) IP Active Pharmaceutical Ingredients (Bulk Drugs)	
84.	ISOTRETINOIN BP/Ph.Eur./USP Active Pharmaceutical Ingredients (Bulk Drugs)	
85.	LAMIVUDINE Active Pharmaceutical Ingredients (Bulk Drugs)	
86.	LAMIVUDINE USP Active Pharmaceutical Ingredients (Bulk Drugs)	

87.	LISINOPRIL USP Active Pharmaceutical Ingredients (Bulk Drugs)	
88.	LISINOPRIL DIHYDRATE BP/Ph.Eur. Active Pharmaceutical Ingredients (Bulk Drugs)	
89.	LOMEFLOXACIN HYDROCHLORIDE Active Pharmaceutical Ingredients (Bulk Drugs)	
90.	LOSARTAN POTASSIUM Active Pharmaceutical Ingredients (Bulk Drugs)	
91.	LOSARTAN POTASSIUM IP/USP Active Pharmaceutical Ingredients (Bulk Drugs)	
92.	LOPERAMIDE HYDROCHLORIDE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
93.	LOPERAMIDE HYDROCHLORIDE USP/BP/EP Active Pharmaceutical Ingredients (Bulk Drugs)	
94.	LUMEFANTRINE Active Pharmaceutical Ingredients (Bulk Drugs)	
95.	LUMEFANTRINE CP/Int.Ph. Active Pharmaceutical Ingredients (Bulk Drugs)	
96.	LEVOCETIRIZINE DIHYDROCHLORIDE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
97.	LEVOFLOXACIN HEMIHYDRATE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
98.	LEVOFLOXACIN USP Active Pharmaceutical Ingredients (Bulk Drugs)	
99.	LEVOFLOXACIN HYDRATE JP Active Pharmaceutical Ingredients (Bulk Drugs)	
100.	LEMOTRIGINE IP/BP/USP/Ph.Eur. Active Pharmaceutical Ingredients (Bulk Drugs)	
101.	LEFLUNOMIDE BP/USP/EP Active Pharmaceutical Ingredients (Bulk Drugs)	
102.	METOPROLOL SUCCINATE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
103.	MEBENDAZOLE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
104.	MESALAMINE USP Active Pharmaceutical Ingredients (Bulk Drugs)	
105.	MESALAZINE BP/Ph.Eur./USP Active Pharmaceutical Ingredients (Bulk Drugs)	
106.	MESALAZINE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
107.	METFORMIN IP Active Pharmaceutical Ingredients (Bulk Drugs)	
108.	METFORMIN HYDROCHLORIDE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
109.	METHYLPHENIDATE HYDROCHLORIDE USP/BP/Ph.Eur. Active Pharmaceutical Ingredients (Bulk Drugs)	



110.	METHYLPHENIDATE BASE Active Pharmaceutical Ingredients (Bulk Drugs)	
111.	METHOTREXATE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
112.	METHOTREXATE BP/USP/Ph.Eur./JP Active Pharmaceutical Ingredients (Bulk Drugs)	
113.	METOCLOPRAMIDE BP/Ph.Eur./JP Active Pharmaceutical Ingredients (Bulk Drugs)	
114.	METOCLOPRAMIDE HYDROCHLORIDE IP/ USP/Ph.Eur. Active Pharmaceutical Ingredients (Bulk Drugs)	
115.	METOPROLOL SUCCINATE BP/Ph.Eur./USP Active Pharmaceutical Ingredients (Bulk Drugs)	
116.	METOPROLOL TARTRATE IP/BP/Ph.Eur. Active Pharmaceutical Ingredients (Bulk Drugs)	
117.	MORANTEL CITRATE Active Pharmaceutical Ingredients (Bulk Drugs)	
118.	MORANTEL TARTRATE BP/Ph.Eur./VET Active Pharmaceutical Ingredients (Bulk Drugs)	
119.	MEMANTINE HYDROCHLORIDE Active Pharmaceutical Ingredients (Bulk Drugs)	
120.	NABUMETONE BP/Ph.Eur./USP Active Pharmaceutical Ingredients (Bulk Drugs)	
121.	NAPROXEN BP/Ph.Eur./USP Active Pharmaceutical Ingredients (Bulk Drugs)	
122.	NIFEDIPINE USP/EP Active Pharmaceutical Ingredients (Bulk Drugs)	
123.	NORFLOXACIN IP Active Pharmaceutical Ingredients (Bulk Drugs)	
124.	OLMESARTAN MEDOXOMIL Active Pharmaceutical Ingredients (Bulk Drugs)	
125.	OLANZAPINE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
126.	OLANZAPINE Ph.Eur./USP Active Pharmaceutical Ingredients (Bulk Drugs)	
127.	ONDANSETRON BASE USP Active Pharmaceutical Ingredients (Bulk Drugs)	
128.	ONDANSETRON IP Active Pharmaceutical Ingredients (Bulk Drugs)	
129.	ONDANSETRON HYDROCHLORIDE DIHYDRATE BP/Ph.Eur./USP Active Pharmaceutical Ingredients (Bulk Drugs)	
130.	ONDANSETRON HYDROCHLORIDE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
131.	OXANTEL PAMOATE Active Pharmaceutical Ingredients (Bulk Drugs)	
132.	OXCARBAZEPINE IP Active Pharmaceutical Ingredients (Bulk Drugs)	

133.	OXCARBAZEPINE USP Active Pharmaceutical Ingredients (Bulk Drugs)	
134.	PANTOPRAZOLE SODIUM USP/IP Active Pharmaceutical Ingredients (Bulk Drugs)	
135.	PANTOPRAZOLE SODIUM SESQUIHYDRATE EP/BP Active Pharmaceutical Ingredients (Bulk Drugs)	
136.	PARACETAMOL (ACETAMINOPHEN) IP Active Pharmaceutical Ingredients (Bulk Drugs)	
137.	PARINTEL EMBONATE BP Active Pharmaceutical Ingredients (Bulk Drugs)	
138.	PAROXETINE HYDROCHLORIDE HEMIHYDRATE Active Pharmaceutical Ingredients (Bulk Drugs)	
139.	PAROXETINE HYDROCHLORIDE HEMIHYDRATE BP/Ph.Eur. Active Pharmaceutical Ingredients (Bulk Drugs)	
140.	PAROXETINE HYDROCHLORIDE ANHYDROUS USP/EP Active Pharmaceutical Ingredients (Bulk Drugs)	
141.	PAROXETINE HYDROCHLORIDE HEMIHYDRATE USP Active Pharmaceutical Ingredients (Bulk Drugs)	
142.	PENTOXIFYLLINE BP/Ph.Eur./USP Active Pharmaceutical Ingredients (Bulk Drugs)	
143.	PERINDOPRIL Active Pharmaceutical Ingredients (Bulk Drugs)	
144.	PERINDOPRIL ERBUMINE BP/Ph.Eur. Active Pharmaceutical Ingredients (Bulk Drugs)	
145.	PERINDOPRIL TERT-BUTYLAMINE BP/Ph.Eur. Active Pharmaceutical Ingredients (Bulk Drugs)	
146.	PIPERAQUINE PHOSPHATE CP Active Pharmaceutical Ingredients (Bulk Drugs)	
147.	PRAZIQUANTEL IP/USP/BP/Ph.Eur. Active Pharmaceutical Ingredients (Bulk Drugs)	
148.	PRIMAQUINE PHOSPHATE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
149.	PROBENECID IP Active Pharmaceutical Ingredients (Bulk Drugs)	
150.	PROGUANIL HYDROCHLORIDE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
151.	PROPRANOLOL HYDROCHLORIDE IP/BP/Ph.Eur. Active Pharmaceutical Ingredients (Bulk Drugs)	
152.	PROMETHAZINE HYDROCHLORIDE IP Active Pharmaceutical Ingredients (Bulk Drugs)	



153.	PYRANTEL EMBONATE BP/Ph.Eur. Active Pharmaceutical Ingredients (Bulk Drugs)	
154.	PYRANTEL PAMOATE IP/USP/IP Active Pharmaceutical Ingredients (Bulk Drugs)	
155.	PYRANTEL TARTRATE B.VET.C Active Pharmaceutical Ingredients (Bulk Drugs)	
156.	PRIMETHAMINE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
157.	PROPAFENONE HYDROCHLORIDE USP/CP/EP/BP Active Pharmaceutical Ingredients (Bulk Drugs)	
158.	QUETIAPINE FUMARATE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
159.	QUETIAPINE HEMIFUMARATE Active Pharmaceutical Ingredients (Bulk Drugs)	
160.	QUININE BISULPHATE (QUININE ACID SULPHATE) IP Active Pharmaceutical Ingredients (Bulk Drugs)	
161.	QUININE DIHYDROCHLORIDE (QUININE ACID HYDROCHLORIDE) IP Active Pharmaceutical Ingredients (Bulk Drugs)	
162.	QUININE SULPHATE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
163.	RABEPRAZOLE SODIUM IP Active Pharmaceutical Ingredients (Bulk Drugs)	
164.	RAMIPRIL IP/BP/Ph.Eur./USP Active Pharmaceutical Ingredients (Bulk Drugs)	
165.	RISEDRONATE SODIUM Active Pharmaceutical Ingredients (Bulk Drugs)	
166.	RISEDRONATE SODIUM Active Pharmaceutical Ingredients (Bulk Drugs)	
167.	RISEDRONATE SODIUM USP Active Pharmaceutical Ingredients (Bulk Drugs)	
168.	RISEDRONATE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
169.	RISPERIDONE BP/Ph.Eur./USP Active Pharmaceutical Ingredients (Bulk Drugs)	
170.	RABEPRAZOLE SODIUM Active Pharmaceutical Ingredients (Bulk Drugs)	
171.	S-ATENOLOL Active Pharmaceutical Ingredients (Bulk Drugs)	
172.	SODIUM ALENDRONATE IP/BP/Ph.Eur. Active Pharmaceutical Ingredients (Bulk Drugs)	
173.	SODIUM VALPROATE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
174.	SODIUM VALPROATE BP/EP/IP/USP Active Pharmaceutical Ingredients (Bulk Drugs)	



175.	STAVUDINE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
176.	SULFASALAZINE BP/USP/Ph.Eur./Int.Ph. Active Pharmaceutical Ingredients (Bulk Drugs)	
177.	SULPHADOXINE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
178.	SULPHADOXINE (SULPHORMETHOXINE SULPHOETHOMIDINE) IP Active Pharmaceutical Ingredients (Bulk Drugs)	
179.	SULPHALENE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
180.	SULPHAMETHOXAZOLE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
181.	S-AMLODIPINE BESYLATE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
182.	SUMATRIPTAN SUCCINATE USP/Ph.Eur. Active Pharmaceutical Ingredients (Bulk Drugs)	
183.	TELMISARTAN Active Pharmaceutical Ingredients (Bulk Drugs)	
184.	TELMISARTAN BP/EP/IP Active Pharmaceutical Ingredients (Bulk Drugs)	
185.	TERBUTALAIN SULPHATE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
186.	TORSEMIDE / TORASEMIDE / ANHYDROUS TORASEMIDE IP/BP/Ph.Eur./USP Active Pharmaceutical Ingredients (Bulk Drugs)	
187.	TORSEMIDE / TORASEMIDE USP/Ph.Eur. Active Pharmaceutical Ingredients (Bulk Drugs)	
188.	TRAMADOL HYDROCHLORIDE BP/Ph.Eur./USP/IP Active Pharmaceutical Ingredients (Bulk Drugs)	
189.	TRIAMTERENE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
190.	TRICLABENDAZOLE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
191.	TRICLABENDAZOLE Active Pharmaceutical Ingredients (Bulk Drugs)	
192.	TRICLOSAN IP Active Pharmaceutical Ingredients (Bulk Drugs)	
193.	TRIMETHOPRIM IP Active Pharmaceutical Ingredients (Bulk Drugs)	
194.	TRAZODONE HYDROCHLORIDE USP/BP Active Pharmaceutical Ingredients (Bulk Drugs)	
195.	TRAZODONE HYDROCHLORIDE EP/USP/BP Active Pharmaceutical Ingredients (Bulk Drugs)	
196.	TAMSULOSIN HYDROCHLORIDE IP Active Pharmaceutical Ingredients (Bulk Drugs)	



197.	VALSARTAN Active Pharmaceutical Ingredients (Bulk Drugs)	
198.	VALSARTAN IP/USP/BP/EP Active Pharmaceutical Ingredients (Bulk Drugs)	
199.	VENLAFAXINE HYDROCHLORIDE USP/Ph.Eur. Active Pharmaceutical Ingredients (Bulk Drugs)	
200.	WARFARIN SODIUM IP Active Pharmaceutical Ingredients (Bulk Drugs)	
201.	WARFARIN SODIUM CLATHRATE IP Active Pharmaceutical Ingredients (Bulk Drugs)	
202.	ZOLEDRONIC ACID Active Pharmaceutical Ingredients (Bulk Drugs)	
203.	ZOLEDRONIC ACID IP Active Pharmaceutical Ingredients (Bulk Drugs)	
204.	ZOPICLONE Ph.Eur. Active Pharmaceutical Ingredients (Bulk Drugs)	
205.	ACETAMINOPHEN USP Active Pharmaceutical Ingredients (Bulk Drugs) For Export - Name of Countries: - Quantity: - Pack Detail: -	
206.	ALENDRONIC ACID USP Active Pharmaceutical Ingredients (Bulk Drugs) For Export - Name of Countries: - Quantity: - Pack Detail: -	
207.	ALFUZOSIN HYDROCHLORIDE BP/USP Active Pharmaceutical Ingredients (Bulk Drugs) For Export - Name of Countries: - Quantity: - Pack Detail: -	
208.	ALLOPURINOL BP/Ph.Eur./USP Active Pharmaceutical Ingredients (Bulk Drugs) For Export - Name of Countries: - Quantity: - Pack Detail: -	
209.	AMODIAQUINE HYDROCHLORIDE USP/FRENCH PHARMACOPOEIA/USP Active Pharmaceutical Ingredients (Bulk Drugs) For Export - Name of Countries: - Quantity: - Pack Detail: -	

